Retatrutide, a new dual agonist of the GLP-1 receptor and glucose-dependent released polypeptide (GIP) binding site , is demonstrating promising results in preliminary clinical studies. Current inquiry https://wavesocialmedia.com/story7074388/retatrutide-emerging-investigations-and-projected-therapeutic-applications